Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 7:46 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 145–168 of 704 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CC5013 Clear all

Conditions: Acute Myeloid Leukemia, Acute Myelogenous Leukemia
Interventions: Azacitidine, Lenalidomide, Best Supportive Care (BSC); Drug · Other
Lead sponsor: Celgene; Industry
Eligibility: 65 Years and older
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 24
States / cities: Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more

Conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions: dalteparin, lenalidomide, dexamethasone, laboratory biomarker analysis; Drug · Other
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Multiple Myeloma, Post Stem Cell Transplant
Interventions: Talquetamab, Talquetamab and Lenalidomide; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Lymphoma
Interventions: Lenalidomide, Vorinostat, Gemcitabine, Busulfan, Melphalan, Rituximab, Dexamethasone, Caphosol, Glutamine, Pyridoxine, Enoxaparin, Stem Cell Transplant, Palifermin; Drug · Procedure
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 15 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myeloma, Multiple
Interventions: Lenalidomide, Ixazomib, Daratumumab Injection, Dexamethasone; Drug
Lead sponsor: Alliance Foundation Trials, LLC.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 79 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 7
States / cities: Bangor, Maine • Boston, Massachusetts • Omaha, Nebraska + 3 more

Conditions: Multiple Myeloma
Interventions: myPRS, Induction 1 - MEL-10+CFZ-TD-PACE, First Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Inter-Therapy - MEL-20+CFZ-TD-PACE (75%), Second Transplant - MEL-80+CFZ-TD-PACE + PBSC (biologic), Consolidation - CFZ-TD-PACE, Maintenance - CFZ-R(T)-D; Device · Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Multiple Myeloma
Interventions: DKN-01 300 mg, DKN-01 600 mg, Standard of Care; Drug
Lead sponsor: Leap Therapeutics, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 3
States / cities: Atlanta, Georgia • Boston, Massachusetts

Conditions: Waldenstrom Macroglobulinemia
Interventions: Thalidomide, Lenalidomide, Rituximab; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Myeloma, Cancer
Interventions: Isatuximab, Lenalidomide, Dexamethasone; Drug
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2033
U.S. locations: 5
States / cities: Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 2 more

Conditions: Leukemia, Myeloid, Acute
Interventions: Lenalidomide, Azacitidine; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hepatocellular Carcinoma
Interventions: Lenalidomide, Sorafenib; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma
Interventions: Laboratory Biomarker Analysis, Lenalidomide, Nivolumab; Other · Drug · Biological
Lead sponsor: David Bond, MD; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 2
States / cities: Atlanta, Georgia • Columbus, Ohio

Conditions: Lymphoma, Large B-Cell, Diffuse
Interventions: Durvalumab, Rituximab, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone, Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 7
States / cities: Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more

Conditions: Multiple Myeloma
Interventions: Daratumumab, Lenalidomide, Bortezomib, Dexamethasone; Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 4
States / cities: Ann Arbor, Michigan • Detroit, Michigan • Rochester, New York + 1 more

Conditions: B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma, T-Cell Non-Hodgkin Lymphoma
Interventions: Ipilimumab, Lenalidomide; Biological · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndrome
Interventions: Not listed
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 14
States / cities: Scottsdale, Arizona • Stanford, California • Lecanto, Florida + 9 more

Conditions: Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma
Interventions: Lenalidomide; Drug
Lead sponsor: Georg Aue, M.D.; NIH
Eligibility: 21 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Lenalidomide, Gemcitabine, Oxaliplatin, Rituximab, Etoposide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 111 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2018
U.S. locations: 13
States / cities: Burbank, California • Orlando, Florida • Atlanta, Georgia + 9 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, CC-99282; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 18
States / cities: Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more

Conditions: Myeloma
Interventions: Bendamustine, Lenalidomide, Dexamethasone, Aspirin, Prophylaxis, Antibiotic, Biweekly Follow Up, Cyclical Follow Up, Restaging, Post-Treatment Follow Up; Drug · Other
Lead sponsor: Robert Redner, MD; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2015
U.S. locations: 22
States / cities: Detroit, Michigan • Steubenville, Ohio • Beaver, Pennsylvania + 13 more

Conditions: Diffuse Large B-cell Lymphoma
Interventions: Tafasitamab, Lenalidomide, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, Tafasitamab placebo, Lenalidomide placebo; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 899 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 47
States / cities: Daphne, Alabama • Anaheim, California • Clovis, California + 44 more

Conditions: Multiple Myeloma
Interventions: Ruxolitinib Oral Tablet [Jakafi], Lenalidomide, Methylprednisolone; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 13
States / cities: Alhambra, California • Bakersfield, California • Encinitas, California + 9 more

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Dexamethasone, Daratumumab, Carfilzomib, Mezigdomide, Iberdomide, ABBV-2001, Pomalidomide; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 602 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2036
U.S. locations: 15
States / cities: Duarte, California • Irvine, California • San Francisco, California + 11 more

Conditions: Multiple Myeloma, Plasma Cell Leukemia
Interventions: Isatuximab; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Chicago, Illinois • Salt Lake City, Utah

Search by objective public record fields.

A Study Being Conducted at Multiple Locations to Compare Safety and Efficacy of Three Different Regimens; (1) High-Dose Lenalidomide; (2) Lenalidomide + Azacitidine; or (3) Azacitidine in Subjects ≥ 65 Years With Newly-Diagnosed Acute Myeloid Leukemia

Dalteparin, Lenalidomide, and Low-Dose Dexamethasone in Treating Patients With Previously Untreated Multiple Myeloma

Talquetamab & Lenalidomide as Post Stem Cell Transplant Maintenance in Multiple Myeloma

Lenalidomide Combined With Vorinostat/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Diffuse Large B-Cell Lymphoma of the ABC Subtype

Study of Lenalidomide/Ixazomib/Dexamethasone/Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM

UARK 2012-02 Trial For High-Risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Thalidomide, Lenalidomide, and Rituximab for Previously Treated Waldenstrom Macroglobulinemia

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

Azacitidine and Lenalidomide for Acute Myeloid Leukemia

Lenalidomide in Combination With a Fixed Dose of Sorafenib for the Treatment of Hepatocellular Carcinoma

Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma

A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

Lenalidomide and Ipilimumab After Stem Cell Transplant in Treating Patients With Hematologic or Lymphoid Malignancies

Multi-center, Survival Data Collection in Subjects Previously Enrolled in Celgene Protocol CC-5013-MDS-003

Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Study of Lenalidomide to Evaluate Safety and Effectiveness in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Bendamustine in Combination With Lenalidomide and Dexamethasone in Refractory or Relapsed Multiple Myeloma

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma